Life Science REIT PLC
LSE:LABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Life Science REIT PLC
LSE:LABS
|
UK |
|
Chimera Investment Corp
NYSE:CIM
|
US |
|
SK Hynix Inc
KRX:000660
|
KR |
|
Globant SA
NYSE:GLOB
|
LU |
|
Compagnie de Saint Gobain SA
PAR:SGO
|
FR |
|
Kenedix Office Investment Corp
TSE:8972
|
JP |
|
Hong Kong Exchanges and Clearing Ltd
HKEX:388
|
HK |
|
Xcel Energy Inc
NASDAQ:XEL
|
US |
|
S
|
Sprint Bioscience AB
STO:SPRINT
|
SE |
|
TechPrecision Corp
NASDAQ:TPCS
|
US |
|
COPT Defense Properties
NYSE:CDP
|
US |
|
E
|
Endurance Technologies Ltd
BSE:540153
|
IN |
Wall St Price Targets
LABS Price Targets Summary
Life Science REIT PLC
According to Wall Street analysts, the average 1-year price target for LABS is 37.74 GBX with a low forecast of 37.37 GBX and a high forecast of 38.85 GBX.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LABS's stock price target?
Price Target
37.74
GBX
According to Wall Street analysts, the average 1-year price target for LABS is 37.74 GBX with a low forecast of 37.37 GBX and a high forecast of 38.85 GBX.
What is the Revenue forecast for Life Science REIT PLC?
Projected CAGR
19%
Over the last 2 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 2 years is 19%.
What is the Operating Income forecast for Life Science REIT PLC?
Projected CAGR
35%
Over the last 2 years, the compound annual growth rate for Operating Income has been 48%. The projected CAGR for the next 2 years is 35%.
